Functional neuroimaging studies have consistently reported abnormalities in the visual cortex in patients with dementia with Lewy bodies (DLB), but their neuropathologic substrates are poorly understood. We analyzed synaptic proteins and choline acetyltransferase (ChAT) in the primary (BA17) and association (BAs18/19) visual cortex in DLB and similar aged control and Alzheimer disease (AD) subjects. We found lower levels of synaptophysin, syntaxin, SNAP-25, and F-synuclein in DLB subjects versus both aged control (68%Y78% and 27%Y72% for BA17 and BAs18/19, respectively) and AD cases (54%Y67% and 10%Y56% for BA17 and BAs18/19, respectively). The loss in ChAT activity in DLB cases was also greater in BA17 (72% and 87% vs AD and control values, respectively) than in BAs18/19 (52% and 65% vs AD and control groups, respectively). The observed synaptic and ChAT changes in the visual cortices were not associated with tau or A-amyloid pathology in the occipital or the frontal, temporal, and parietal neocortex. However, the neocortical densities of LBs, particular those in BA17 and BAs18/19, correlated with lower synaptic and ChAT levels in these brain areas. These findings draw attention to molecular changes within the primary visual cortex in DLB and correlate with the neuroimaging findings within the occipital lobe in patients with this disorder.
INTRODUCTION
Occipital lobe hypoperfusion (1Y3) and glucose hypometabolism (4Y7) have been consistently reported in both probable and autopsy-confirmed cases of dementia with Lewy bodies (DLB) (8, 9) . Although these findings have low sensitivity and specificity for routine clinical use (4), they may offer an explanation for the high prevalence of visual symptoms, including visuoperceptual deficits and visual-related behavioral symptoms (e.g. visual hallucinations) in patients with DLB (10, 11) .
The neuroimaging findings are at variance with the limited neuropathology detected in the occipital cortex of DLB. Thus, the LB density is the lowest in this area (4, 12) , with Brodmann area 17 (BA17) having a significantly lower density of LBs and Lewy neurites in relation to BA18 and BA19 (13) . Even at the neurochemical level, the tau (paired helical filaments' accumulation) and amyloid (AA) protein content in the occipital lobe do not discriminate between older control subjects and those with the LB diseases, including DLB and Parkinson disease (PD) with and without dementia (14) . However, patients with DLB do have significantly lower choline acetyltransferase (ChAT) activity in their visual association cortex compared with those with AD and/or control subjects (15) .
Because components of the cholinergic neurotransmitter system (e.g. ChAT activity) correlate with a loss of synaptophysin in the midYfrontal neocortex in DLB (16), we undertook a biochemical analysis of synaptic proteins (synaptophysin, syntaxin, SNAP-25, and F-synucleins) of autopsy-proven DLB, AD, and age-matched control subjects with no neurologic disorder. The aim of the study was to explore whether the primary and association visual cortices in DLB subjects exhibit changes in the level of these synaptic proteins, and if so, how they are related to the ChAT changes seen in these areas. postmortem delay, cortical LB score, LB disease diagnostic category, and Braak stage) are provided in Table 1 . Use of autopsy brain tissues was approved by the Local Research Ethics Committee of Newcastle and North Tyneside Health Authority.
Clinical data of DLB, AD, and control subjects were obtained from the Institute for Ageing and Health database. The review of the clinical histories for the control subjects showed no presence of cognitive impairment or psychiatric and/or neurologic disorders. Clinical information for the cognitive functioning of the AD subjects was recorded at their baseline and contained Mini-Mental State Examination and Cambridge Assessment for Mental Disorders in the Elderly information.
The clinical diagnosis of DLB was based on the consensus clinical criteria (17, 18) . Clinical assessments were repeated annually until death and included a standardized psychiatric history (History and Aetiology Schedule) (19) , assessment of cognitive function using the CAMDEX (20) , a standardized physical examination including the modified Unified Parkinson's Disease Rating Scale (21) , and assessment of psychosis using the Columbia University Scale for Psychopathology in Alzheimer's disease (22) . The presence of psychotic features, including visual hallucinations, auditory hallucinations, and delusional phenomena (including delusional misidentification), was estimated according to Burns et al (23) .
Neuropathology
At autopsy, the right cerebral hemisphere, cerebellum, and brainstem were fixed in formalin; samples were embedded in paraffin, and 6-Km-thick sections were examined using standard neurohistopathological stains, including hematoxylin and eosin for general histology, cresyl fast violet for neuronal population density, and Loyez method for myelin staining. Further neuropathologic assessment was done on paraffinembedded tissue sections immunostained for ubiquitin (DAKO Glostrup, Denmark), Tau2 (Sigma, St. Louis, MO), AT8 (Endogen, Pierce, Rockford, IL), A-amyloid (DAKO), and >-synuclein (Novocastra Laboratories, Ltd, Newcastle upon Tyne, UK). The densities of amyloid plaques, neurofibrillary tangles, and LBs from frontal (BA9), temporal (BA20Y22), parietal (BA40), and occipital lobe (BA17 and BAs18/19) were recorded. The >-synucleinYimmunoreactive Lewy neurites in each region were examined at a magnification of 250Â, and their density was expressed on a semiquantitative scale of 0 to 3 (0, absent; 1, sparse; 2, moderate; and 3, frequent [24] ). Concomitant neurofibrillary pathology was assessed using the Braak staging (25) . The neuropathologic diagnosis of DLB and LB staging was established according to criteria recommended by the First and Third Report of the DLB Consortium (17, 18) , whereas the neuropathologic diagnosis of AD was consistent with CERAD (Consortium to Establish a Registry for Alzheimer's Disease) (26) and NIA-Reagan (27) neuropathologic criteria.
Protein Extraction and Quantitative Assays
Left cerebral hemispheres were coronally sliced at 1-cm intervals and snap-frozen for neurochemical studies at the time Total cLB score represents a sum of semiquantitative scores from the transentorhinal (TE), anterior cingulate (AC), temporal (T), frontal (F), and parietal (P) cortex using the scoring scheme recommended by the Third Report of the DLB Consortium, where presence of LBs is scored as: 0, none; 1, few; 2, moderate; 3, high; 4, very high. The LBD diagnostic categories are defined by a total cLB score as follows: L (Limbic) = 2 to 9 (2 to 6 in TE and AC and 0 to 3 in T and F and P); DN (diffuse neocortical) = 7 to 20 (4Y8 in TE and AC; +3Y12 in T and F and P) (18) . Lewy neurites were not detected in neocortical areas in AD or control cases, whereas in DLB cases, BA17 and BAs18/19 were devoid of Lewy neurites.
Values represent mean T SEM (range of autopsy. For biochemistry, brain tissue from primary (BA17) and association (BAs18 and 19) visual cortex (0.5 g wet weight gray matter) was subdissected from the frozen slices (R.H. Perry et al, unpublished data) and used for the protein extraction and quantitative assays. The extraction of synaptic (synaptophysin, syntaxin, and SNAP-25) and heat-stable proteins (F-synuclein) was done according to a previously published protocol (28) . Briefly, the brain tissue was homogenized in 0.32 mol/L sucrose, and 100 KL of this brain homogenate was retained and used for F-synuclein analysis. The rest of the brain homogenate was subdivided into 2 portions and used for extraction of synaptic proteins (precipitated with 1 mol/L NaCl) and heatstable proteins (precipitated with 60% ammonium sulfate).
Total levels of protein in the extract were determined using the Lowry protein assay, based on the reaction of Cu + produced by the oxidation of peptide bonds, with Folin-Ciocalteu reagent (29) . There were no significant differences in the total protein concentrations between DLB, AD, and control groups (BA17: 4.63 T 1.75 Kg/mL vs 3.59 T 1.21 Kg/mL vs 4.13 T 1.22 Kg/mL for DLB, AD, and control groups, respectively, F = 0.575, p = 0.567; BAs18/19: 5.20 T 1.19 Kg/mL vs 5.49 T 1.00 Kg/mL vs 5.74 T 1.08 Kg/mL for DLB, AD, and control groups, respectively, F = 0.057, p = 0.945). All measurements were done blind to clinical and neuropathologic diagnoses.
Description of Immunoprobes
The characteristics of the synaptic immunoprobes against synaptophysin, syntaxin, and SNAP-25 (mAbs EP10, SP8, and SP12, respectively) have been previously published (30) . The level of F-synuclein was estimated with mAb 21H12 (antiYF-synuclein antibody), the epitope of which remains unknown. This immunoprobe was raised against a 65-AA sequence of F-synuclein and was screened against >-and A-synuclein peptides to identify specific reactivity to the F-synuclein protein (31) . None of the biochemical measures were influenced by postmortem delay, fixation, or agonal state, similarly to previous studies (32, 33) .
Immunoassays
Indirect ELISA was used to determine the protein level of synaptophysin (1:10 dilution), syntaxin, SNAP-25, and F-synuclein (all used in 1:100 dilution). Briefly, triplicates of double dilutions of the antigen over 6 wells were coated overnight at 4-C using carbonate-bicarbonate buffer, washed in 0.05% Tween, blocked with 1% dried skim milk, and incubated for 1 hour at 37-C. Plates were washed again and incubated for 1 hour at 37-C with primary antibodies to the antigen of interest and diluted in 0.05% Tween in PBS (pH 6.8). After another wash in 0.05% Tween in PBS, plates were incubated with secondary antibodies conjugated to horseradish peroxidase and incubated again for 1 hour at 37-C. Colorimetric analysis of reaction with trimethyl benzadine was performed, and the reaction was quenched after 10 minutes with 2N H 2 SO 4 . Plates were read with Vmax plate reader (Molecular Devices, Sunnyvale, CA), and assay curves were plotted using SOFTmaxPro (Version 4.7.1; Molecular Devices). All values were normalized for 0.3-mL fraction from 0.3 to 0.5 g of brain tissue and expressed as relative arbitrary units of immunoreactivity, similar to a previous report (28) .
To determine ChAT activity, brain homogenates were prepared from 20-to 30-mg frozen brain tissue from both analyzed area. The ChAT activity was measured using the modified Fonnum radiochemical method (34, 35) , which includes both zero time (0 minutes) and 90 minutes of incubation. The 
Statistical Analysis
Statistical analysis was performed using SPSS v.19. Because data were not normally distributed (Shapiro-Wilk test), group differences were tested with the Kruskal-Wallis one-way analysis of variance test, whereas the specific sample pairs for significant differences were addressed with the Mann-Whitney U test with a Bonferroni correction for multiple comparisons. The strength of association (monotonic relationship) between variables was determined by the Spearman rank correlation. Significance of analysis was set at p = 0.05.
RESULTS

Neuropathologic Features in Visual Areas of the DLB Group
The total cortical LB score was significantly higher in the DLB cases (p G 0.0001; Table 1 ). As expected, AD subjects had the highest density of both neurofibrillary tangles and amyloid plaques in occipital areas, whereas the control group had only an insignificant amount of plaques. The DLB cases had a lower density of neurofibrillary tangles and amyloid plaques in BAs18/19 versus AD (p G 0.0001) but a significantly higher density of LBs compared with both AD and control groups (p G 0.0001). Vascular abnormalities in the occipital lobes were not detected in any of the control subjects, but they were present in 30% of the AD group and in only 2 DLB cases (Table 1) .
Synaptic Protein Levels in Visual Areas of DLB Subjects
The DLB subjects had significantly lower levels of synaptic (synaptophysin, syntaxin, SNAP-25, and F-synuclein) proteins in both the primary and association visual cortices compared with AD and control subjects ( Table 2 ). The reduction of these proteins was more pronounced in BA17 (3-to 5-fold and 2-to 3-fold lower level of synaptophysin, syntaxin, SNAP-25, and F-synuclein in comparison with those in the controls and AD subjects) than in BAs18/19 (1.5-to 3-fold lower). Similar significant reductions, with more pronounced changes in BA17 than in BAs18/19, were apparent in ChAT activities for the DLB group (Table 2) .
Control subjects had higher levels of synaptophysin (F = 2.930, p = 0.097) and syntaxin (F = 5.416, p = 0.027) but not of SNAP-25 (F = 0.658, p = 0.424) or F-synuclein (F = 0.061, p = 0.807) in BA17 compared with BAs18/19 ( Table 2 In the primary visual cortex in DLB subjects, previously reported ChAT activities correlated with the expression of synaptophysin, syntaxin, SNAP-25, and F-synuclein, whereas these correlations did not reach significance for the secondary visual cortex (Table 3 ). There was no correlation between ChAT activities and levels of synaptic proteins in both BA17 and BAs18/19 in the control group.
Correlative Biochemical and Neuropathologic Analysis
We conducted a correlative biochemical-neuropathologic analysis to address whether the changes in occipital lobe synaptic content in DLB and AD groups were associated with local or more remote neuropathology (Table 4) . Neurofibrillary and amyloid pathology in the frontal, temporal, parietal, and occipital lobes (BA17 and BAs18/19 analyzed separately) did not play a major role in the decline of synaptic proteins and ChAT in DLB and AD subjects, with the exception of the density of neurofibrillary tangles in the frontal lobe (negatively correlated with BA17 F-synuclein levels; r = j0.786, p = 0.036) and BA17 (negatively correlated with BAs18/19 syntaxin levels; r = j0.732, p = 0.039). Interestingly, the amyloid load of BA17 and BAs18/19 was positively correlated with the BA17 F-synuclein in AD subjects only. However, the presence of LBs in the temporal, parietal, and occipital lobes was negatively correlated with synaptic proteins and ChAT activity in BA17 but not in the same manner in BAs18/19 (syntaxin and SNAP-25) in DLB subjects. In contrast, the presence of Lewy neurites did not seem to influence the level of synaptic proteins and ChAT activity in the occipital lobe (Table 4 ).
DISCUSSION
We demonstrate significant changes in synaptic proteins and ChAT activities in the primary and association visual cortices in DLB. This loss occurs in the presence of minor histopathologic changes detected in these areas, suggesting that low levels of LB pathology (consisting of >-synuclein aggregates) might instigate or result in these changes either on their own or with amyloid-A enhancing the >-synucleinYinduced synapse damage, as recently demonstrated in vitro (38) .
There are some limitations to the present study. We focus here on the occipital lobe rather than including a broader comparison with other neocortical brain regions. Therefore, the results reported herein will necessarily have to be placed into context with results of comparable analyses to be obtained from other brain regions. Moreover, because ChAT data on cases of PD with dementia were not available for the present study, such cases were not included. Thus, it may also be difficult at this time to know how to incorporate the present results into the broader range of diseases with LB pathology. Moreover, we did not perform biochemical measurements of A-amyloid in the cortical samples. Nevertheless, the present data suggest possible correlates of the neuroimaging findings of hypoperfusion and molecular substrates of dysfunction that are characteristic of the occipital lobes in subjects with DLB.
Synaptic loss (assessed using synaptophysin and SNAP-25 immunoprobes) in the medial temporal lobe and the frontal neocortex has been previously reported in DLB with and without concomitant AD neuropathology (39Y47). Some of these studies have related the substantial depletion of synaptophysin and SNAP-25 in DLB to the presence of AD pathology, with the synaptic loss being similar to that observed in AD (40, 42) . A larger clinicobiochemical and neuropathologic correlative study in AD also reported a significant negative correlation between neurofibrillary tangles and synaptophysin expression (48) . In contrast, individuals with pure DLB and those with LBs without dementia have either been reported to have unchanged levels of synaptophysin versus control subjects (43) or somewhat lower levels of synaptic proteins but not to the extent observed in AD (40, 45, 46) . We demonstrate that synaptic changes in DLB occur in the presence of low levels of LB pathology but not of AD pathology or Lewy neurites. Thus, our results contrast with those in previous reports. Nevertheless, we show that in DLB, in particular, the loss of synaptic proteins might reflect cortico-cortical disconnectivity, similar to that described in AD (49, 50) . In support of this are recent findings of reduced fractional anisotropy restricted predominantly to the parieto-occipital white matter tracts in DLB subjects only (51) , highlighting the potential importance of white matter tract changes as a possible mode for >-synuclein propagation in DLB.
Our findings of differential synaptic protein expression in DLB visual areas point toward distinct neurobiologic mechanisms underlying the synaptic changes in BA17 and BAs18/19. Thus, whereas the decline in synaptic proteins in the primary visual cortex might be explained by LB pathology alone, it seems that the slightly higher LB score in BAs18/19 may have resulted in elevated synaptic protein levels in these brain areas. A biochemical study reported that >-synuclein aggregates (considered by some to be early stages of LBs [52] ) were accompanied by an increase in syntaxin and synaptophysin levels (53) . This would be in agreement with an increase in the Nterminal end of >-synuclein in this brain area (Elizabeta B. Mukaetova-Ladinska, unpublished data). These findings have now been further confirmed in a transgenic >-synuclein animal model in which >-synuclein aggregates contribute to the redistribution of t-SNARE synaptic proteins in the absence of major quantitative synaptic changes, as seen on immunoblots (54) . We have previously reported upregulation of neocortical synaptic proteins (synaptophysin, syntaxin, and SNAP-25) accompanied by MAP2 and >-synuclein increase at the time of emerging neurofibrillary pathology in AD (28) . These findings provide further support for the concept that the initial stages of neurodegenerative pathology, including LB and neurofibrillary pathology, are accompanied by reorganization of presynaptic end terminals.
Our results showing depleted syntaxin levels in DLB individuals are in contrast to a previous report of upregulation of the syntaxin gene (syntaxin 8) in nigral dopaminergic neurons in vitro (55) and unchanged striatum syntaxin levels in a transgenic animal model of PD (54) . Because oxidative stress is a primary pathogenic mechanism of nigral dopaminergic cell death in PD and other LB-bearing diseases (56) , this raises the possibility of highly selective changes occurring in brain areas harboring dopaminergic neurons rather than uniformly in all brain areas. However, we cannot exclude the possibility that expression patterns of synaptic proteins may vary in different systems (e.g. tissue culture and transgenic animal models vs human cerebral tissue). The loss of syntaxin within the occipital lobe parallels the loss of another SNARE protein, SNAP-25, and indicates that the t-SNARE complex is substantially impaired in DLB, a similar finding to our previous report of t-SNARE loss in the LB variant of AD but not pure AD (57) . This may thus underlie the characteristic profound neurotransmitter deficit in DLB. In support of this is our finding of significant ChAT depletion within the same areas.
A decrease of F-synuclein in the occipital lobe suggests the possibility of a generalized decrease in synaptic proteins in DLB subjects. This is supported by correlations between the level of F-synucleins with the level of synaptophysin, syntaxin, and SNAP-25 in both the primary and secondary visual cortex in DLB. Our results are in contrast to those of a previous study that reported unchanged level of F-synuclein mRNA in DLB neocortex (58) . This decrease in F-synuclein in DLB appears in areas that have minimal >-synuclein and neurofibrillary pathology in contrast to AD subjects who had a substantially higher density of neurofibrillary tangles in both analyzed visual areas. This is notable because F-synuclein has recently been implicated in tubulin polymerization and inducing microtubule bundling (59) . Thus, the observed decrease in AD subjects (all having Braak stage V at the time of their death) may indicate early microtubule disassembly, preceding the overt neurofibrillary pathology occurring in the primary and secondary visual cortex in Braak stage VI.
The truncation and hyperphosphorylation of tau protein alone, however, cannot be the explanation for the F-synuclein decline in DLB because our group had a lower Braak stage. Interestingly, a previous study failed to detect F-synuclein in DLB brain lysates (60); thus, our findings of up to 86% lower F-synuclein levels would be in keeping with the results of the latter study. Another explanation for the lower level of F-synuclein may be attributed to the greater social submissiveness of DLB subjects compared with that of AD patients because F-synuclein mRNA can be regulated via behavioral patterns, with higher levels found widespread in all neocortical areas in dominant subjects only (61) .
In summary, we describe the presence of substantial depletion of synaptic proteins in the occipital lobes of subjects with DLB that, except for a relatively minor LB pathology, is not associated with overt neuropathology. Further studies will need to concentrate on questions examining whether the depletion of synaptic proteins and ChAT reflect pathologic changes (including amyloid-A and >-synuclein oligomers) in the afferent input and/or an arrest in synaptic remodeling in the primary and association visual areas of DLB patients. Our finding of a greater synaptic protein depletion in the primary than in the association visual cortex in DLB needs to be explored further to determine its clinical usefulness in terms of developing novel diagnostic tools and/or pharmacologic treatments for DLB patients, particularly those with prominent visual spatial deficits and persistent visual hallucinations.
